Novo Nordisk A/S (ADR) (NYSE:NVO) fell -0.34% during previous trade. DNB Markets issued rating on the stock of Novo Nordisk A/S (ADR) (NYSE:NVO) in a research note issued to investors on Oct-31-16, the stock received “Downgrade” rating from Buy to Hold. Additionally Citigroup issued their verdict on the stock of the company, on record date of Oct-31-16 the stock was “Downgraded” from Buy to Neutral besides that on Oct-28-16 Novo Nordisk A/S (ADR) (NYSE:NVO) was “Downgraded” by BofA/Merrill from Neutral to Underperform. Furthermore on Sep-23-16 the stock was “Initiated” by Piper Jaffray as Neutral.

Novo Nordisk A/S (ADR) (NYSE:NVO) shares ended last trading session at the price of $35.54 whereas a number of traders indicating mean target price will hit $35.10 over the next twelve months, mean value of price target most recently revised on 10/31/16. Novo Nordisk A/S (ADR) (NYSE:NVO)’s highest estimates of price target are $35.10 and low forecast is $35.10 based on the opinion of 1 analysts. The price target estimates represents a standard deviation of 0.00. However brokerage recommendations suggests an ABR of 3.00 based on calls of 3 experts, where 0 brokers polls the stock a Strong Buy, 0 suggest the stock a Buy, 3 suggest Hold, 0 are rating the stock as Sell while 0 as Strong Sell.

Novo Nordisk A/S (ADR) (NYSE:NVO) is expected to release the earnings of its current quarter on 10/28/16. The company is expected to release $0.53 EPS for current quarter according to 1 analysts whereas the company reported $0.48 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $0.53 and high estimate of $0.53. For the current year Novo Nordisk A/S (ADR) (NYSE:NVO) has set to release EPS of $2.22 as per the sentiments of 2 analysts, however according to 2 analysts, the company expected to release $2.33 EPS for next year.

Novo Nordisk A/S (ADR) (NYSE:NVO)’s average revenue estimates for the current quarter are $4.26B according to 1 number of analysts. However its lowest revenue estimates are $4.26B and highest revenue estimates are $4.26B. A year ago the company’s sales were $4.24B. Its yearly sales growth estimates are 0.50%. For the current year the company has fixed $16.28B revenues, as per the opinion of 2 analysts. For the current year the company has low revenue estimates of $16.16B in contradiction of high revenue estimates of $16.41B. Whereas for the next year revenues are set at $16.86B by 2 analysts.

The stock exchanged hands 9,064,100 shares versus average trading capacity of 3.71M shares, while its shares’ total market worth is $71.80B along with 2.06B outstanding shares. Novo Nordisk A/S (ADR) (NYSE:NVO) shares were trading -38.11% below from the 52-week high price mark of $57.43 and +2.87% above from the 52-week price bottom of $34.55. However the company observed 52 week high price on 12/30/15 and witnessed 52 week low price on 10/28/16. The company’s price sits -18.39% below from its 50-day moving average of $42.10 and -29.91% away from the stock’s 200-day moving average which is $50.12. Novo Nordisk A/S (ADR) (NYSE:NVO)’s price to sales ratio for trailing twelve month stands at 4.46, whereas its price to book ratio for most recent quarter sits at 14.45. However the company’s price to cash per share for most recent quarter stands at 32.31. Its price to free cash flow for trailing twelve months is 23.89.